Molbio Diagnostics IPO Fully Subscribed on Day Two; Grey Market Premium Signals Massive Listing Surge

Molbio Diagnostics IPO Fully Subscribed on Day Two; Grey Market Premium Signals Massive Listing Surge​

Goa-based point-of-care molecular diagnostics company, Molbio Diagnostics, witnessed a robust display of investor interest as its initial public offering (IPO) achieved complete subscription by 10:30 am on August 11. The IPO generated significant demand, solidifying the market's confidence in the growing diagnostic sector.

The Rs 940-crore IPO received bids for approximately 89,13,438 equity shares against the offered amount of 81,58,529 lakh shares. Non-institutional investors led the demand with a subscription rate of 1.16 times, while the retail portion was subscribed 1.11 times.

IPO Market Demand and Grey Market Premium​

The issue, which opened on August 10th and closes on August 12th, is currently commanding substantial momentum in the grey market (GMP). One indicator tracked by investors showed a premium of Rs 124 over the upper end of the price band.

IPO Watch also tracked a similar positive premium, implying that the stock could potentially deliver a listing gain nearing 16 percent above the ₹807 maximum offer price. Investors are reminded that the grey market premium is an unofficial indicator and should not be considered a guarantee of actual listing returns.

Anchor Investor Participation Highlights​

Prior to the public subscription, Molbio Diagnostics successfully raised Rs 281.5 crore from anchor investors. The company allotted 34.87 lakh equity shares to 33 anchor entities during this process.

Prominent global participation included Goldman Sachs, which committed Rs 30 crore. International Finance Corporation (IFC) and BlackRock Global Funds also contributed Rs 20 crore each to the allocation.

Strategic Allocation in Anchor Book​

Domestic mutual funds played a major role in the anchor allocation, securing 23.54 lakh shares across nine domestic schemes. The list of participating mutual funds included HDFC Mutual Fund and Kotak Mahindra Asset Management Company.

The allotment process also saw two life insurance companies acquiring 2.65 lakh shares, valued at Rs 21.44 crore.

IPO Structure: Fresh Issue vs Offer for Sale (OFS)​

The total public issue of Rs 940 crore is composed of a fresh issue totaling Rs 200 crore and an offer for sale (OFS) representing 91.66 lakh shares, valued at around Rs 739.7 crore from existing shareholders. This structure highlights a mix of capital infusion and current promoter/shareholder liquidity needs.

Fund Utilization Plan Details​

Molbio Diagnostics has outlined the intended use of the funds raised through its fresh issue. A portion amounting to Rs 105.5 crore will be used by its subsidiary Bigtec to establish a dedicated research and development facility and Centre of Excellence. This allocation also covers essential office space for the company and its entities.

An additional Rs 72.2 crore is earmarked for purchasing critical plant, machinery, and equipment necessary for scaling up manufacturing operations in both Goa and Visakhapatnam. The remaining funds will be allocated for general corporate purposes.

About Molbio Diagnostics​

Molbio Diagnostics operates as a point-of-care molecular diagnostics company based in Goa, backed by Temasek and the Motilal Oswal Group. Its flagship product is the Truenat platform, a portable molecular diagnostics system designed to identify infectious and non-communicable diseases. The company currently provides molecular diagnostic tests covering 30 diseases across 43 assays, enabling decentralized testing even in resource-constrained settings.